Group 1 - The core viewpoint of the article indicates that the company, 莱茵生物 (Rhein Biotech), primarily focuses on functional ingredients and currently has no plans for large-scale production of natural pigments [1] Group 2 - The company engages in investor interactions to clarify its business direction and product focus [1] - The absence of plans for natural pigment production suggests a strategic emphasis on its existing product lines rather than diversifying into new areas at this time [1]

Group 1 - The company has a certain amount of CBD inventory [1] - The factory in Indiana, USA, has the production capacity for industrial hemp extracts, allowing the company to respond promptly to market demands [1]

Group 1 - The core viewpoint is that if the FDA in the United States cancels synthetic dyes, there will be a significant increase in demand for natural dyes, but the company currently has no plans for large-scale production of natural dyes [2][3] - The company primarily focuses on functional ingredients and does not have immediate plans to adjust production to meet potential demand for natural dyes [2]

Core Viewpoint - The company is advancing the approval and market entry of its newly developed steviol glycoside, RebM2, which has received GRAS certification in the U.S. and is nearing domestic approval in China, indicating significant potential for growth in the natural sweetener market [1][2][3]. Group 1: Product Development and Market Potential - RebM2 is a rare, high-value steviol glycoside that meets the increasing demand for low-calorie, high-sweetness solutions in the context of global sugar reduction initiatives [2]. - The product offers a sweetness level 150 to 200 times that of sucrose, with zero calories and a favorable taste profile, addressing the limitations of traditional steviol glycosides [2][3]. - The company has successfully improved the production efficiency and cost-effectiveness of RebM2 through enzyme conversion methods, enhancing its solubility and stability [3]. Group 2: Strategic Importance and Future Plans - The completion of the public consultation phase for RebM2 in China is a crucial step for the company to accelerate its market promotion and sales efforts [3]. - The company plans to focus on the deep development of RebM2, aiming to innovate applications and expand its product matrix [4]. - The synthetic biology workshop is set to commence operations in September 2024, enabling mass production of RebM2 [3].

Core Insights - The company has developed RebM2, a natural sweetener that overcomes the taste limitations of traditional steviol glycosides, offering "zero calories, high safety, and a taste close to sucrose" as its main advantages [1]. Product Development - RebM2 has successfully passed the public announcement period for new food additives in China, distinguishing itself from other steviol glycosides [3]. - The product can be combined with low-intensity sweeteners like erythritol and allulose, as well as high-intensity sweeteners such as RA and monk fruit glycosides, to create customized sweetening solutions [1]. Market Application - RebM2 has been validated in various application scenarios, including dairy products, beverages, baking, and seasonings, indicating a promising future market potential [1].

人民财讯8月19日电，莱茵生物（002166）8月19日在互动平台表示，国内市场方面，公司所申报的甜菊 糖苷（酶转化法）RebM2作为食品添加剂新品种，其征求意见稿公示阶段已于8月14日结束，公司积极 推动其后续的审批工作；海外市场方面，今年2月公司RebM2已通过美国FDAGRAS认证，可在美国食 品饮料市场合法销售。RebM2产品由公司研发团队独家开发，未来有望成为公司新的利润增长点。 ...

Core Insights - The announcement from the National Center for Food Safety Risk Assessment indicates that the application for Steviol Glycosides (enzyme conversion method) Reb M2 as a new food additive has successfully completed the public consultation phase, paving the way for its gradual entry into the domestic food and beverage market [1] - The global sugar reduction movement is reshaping the food industry, driven by WHO recommendations to limit free sugar intake to below 10% of total energy and China's "Healthy China Action (2019-2030)" initiative, which emphasizes sugar reduction as a key aspect of national health management [1] - The introduction of Reb M2 signifies a technological turning point in the sweetener industry, overcoming the taste limitations of traditional plant-extracted sweeteners and filling the market gap for "high sweetness and natural flavor balance" [1] Industry Analysis - Natural steviol glycosides primarily consist of Stevioside, RebA, and RebC, with Stevioside and RebA accounting for over 80% of the total, both of which exhibit significant aftertaste issues that limit their application in high-end food products [2] - Reb M2 offers a unique advantage, being 150-200 times sweeter than sucrose while having zero calories and high safety, with a sweetness release curve characterized by "front sweetness soft, middle sweetness full, and back sweetness short," effectively addressing the delayed sweetness issue of traditional plant-extracted steviol glycosides [2] - The vast market potential of Reb M2 is attributed to its broad applicability, allowing it to be blended with low-sweetness sweeteners like allulose and erythritol to optimize cost and taste, or with high-sweetness sweeteners like sucralose to mask metallic aftertaste and reduce usage [2] - Reb M2 has completed empirical research across over 20 food categories, covering core sectors such as dairy products, beverages, baking, and condiments, indicating its versatility and market readiness [2] - The launch of Reb M2 is set to reconstruct the sweetness logic in the food industry through technological innovation, facilitating the transition of the steviol glycoside industry from traditional extraction processes to green biomanufacturing, and opening new avenues for companies like Rhein Biotech in the health food and beverage market [2]

Group 1 - The stock price of Rhine Biotech experienced a rapid increase on August 13, with a rise of over 2% within 5 minutes [1] - As of 10:54 AM on August 13, the stock was priced at 8.6 yuan, with a trading volume of 5.02 billion yuan and a turnover rate of 13.25% [1] - Rhine Biotech is part of the traditional Chinese medicine sector, focusing on the research, production, and sales of plant extracts [1] Group 2 - The company's products are widely used in food, health products, and cosmetics [1] - On August 13, the net outflow of main funds for Rhine Biotech was 3.05 million yuan, accounting for 0.08% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 99.95 million yuan, representing 2.62% of the circulating market value [1]

据了解，莱茵生物在合成生物学领域的布局可追溯至2016年，公司先后与中国科学院天津工业生物技术 研究所、江南大学等科研机构合作，深耕天然甜味剂及生物多糖的生物合成技术。目前已建立桂林莱茵 合成生物技术有限公司和成都赛迪科生物科技有限公司两大研发平台，分别聚焦天然甜味剂和生物多糖 领域。 截至2024年9月，莱茵生物已获得8项合成生物学相关专利授权，另有10项专利申请处于受理状态。其 中，2024年6月某一创新型甜叶菊RM系列产品已获得Self-GRAS认证，具备商业化条件；与江南大学陈 坚院士团队合作研发的罗汉果甜苷V全合成技术，更使公司成为业内首家跑通该技术路径的企业，为解 决传统种植模式的局限性提供了全新方案。 据了解，此次通过FDA GRAS认证的瑞鲍迪苷M2，是甜菊糖苷类甜味剂中的稀有高价值单体。相较于 市场上流行的RebD、RebM等成分，RebM2在甜味特性、口感纯净度、稳定性及溶解性等方面均具优 势，与其他甜味剂复配时能显著提升整体效果，应用场景覆盖食品、饮料、膳食补充剂等多个领域。 值得关注的是，莱茵生物采用酶转化法生产RebM2，在效率、成本和质量上形成显著竞争力，有效解决 了传统生产工艺产 ...

Group 1 - As of August 12, 23 stocks have a 5-day trading volume ratio exceeding 5 times [1] - Rhine Biotech has a 5-day trading volume ratio of 8.64 times, indicating significant trading activity [1] - Other companies such as Jiangte Motor, Hebai Group, and Hongyu Co., Ltd. also have 5-day trading volume ratios exceeding 7 times [1]